MetaCap

Cellectar Biosciences (CLRB) vs Vyome (HIND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cellectar Biosciences (CLRB) has outperformed Vyome (HIND) over the past year, losing 72.1% versus a loss of 75.9%. Over five years, CLRB leads with a -99.6% price change compared with -100.0% for HIND. Vyome is the larger company by market cap ($8.4 million vs $8.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLRB-72.13%HIND-75.90%
+47%-17%-82%
Nov 21, 20251 yearNov 20, 2026
CLRB-99.65%HIND-100.00%
+15%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLRB versus HIND key metrics
MetricCLRBHIND
Share price$0.797$1.20
Market cap$8.00M$8.42M
1-day change-11.50%-17.24%
YTD return-72.98%-65.12%
1-year return-72.13%-75.90%
5-year return-99.63%-100.00%
P/E ratio (TTM)—0.25
EPS (TTM)$-2.34$4.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$319.71K
Revenue growth (YoY)—+24.43%
Net income (latest FY)$-21.79M$-10.26M
Gross margin—68.43%
Operating margin—-3269.35%
Net margin—-3209.75%
52-week high$4.70$5.88
52-week low$0.7596$1.20
Distance from 52-week high-83.04%-79.59%
Analyst consensusnonestrong_buy
Avg. price target upside+1342.91%+635.83%
Average volume97.96K13.92K
Shares outstanding10.04M7.02M
Employees119
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cellectar Biosciences

CLRB stock →

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Vyome

HIND stock →

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

CLRB vs HIND FAQ

Which is bigger, Cellectar Biosciences or Vyome?

Vyome (HIND) is larger, with a market capitalization of $8.42M compared with $8.00M for Cellectar Biosciences (CLRB).

Which stock has performed better over the past year, CLRB or HIND?

CLRB returned -72.13% over the past 12 months, compared with -75.90% for HIND (price return, excluding dividends). Past performance does not predict future results.

Are Cellectar Biosciences and Vyome in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons